Kurin

What Kurin does

Kurin, Inc. is a privately held, certified minority-owned medical device company headquartered in San Diego, California, founded in 2015. The company develops and commercializes blood culture collection devices that reduce false-positive blood culture results by passively diverting the initial ~0.15 mL of blood — the aliquot most likely to contain skin contaminants — before it enters the culture bottle. The patented Kurin Lock (the first FDA 510(k)-cleared passive blood culture diversion device, K162233, 2017) requires no additional user steps and adds no steps to the clinician's workflow. The product family has since expanded to include the Kurin Jet (next-generation diversion device launched July 2023, positioned as the fastest path to sub-1% contamination rates), Kurin Advance (a push-button safety needle), the Kurin PIV18 peripheral IV configuration, and the Kurin Outcomes & Kurin Intelligence data and education platform. Customers are U.S. hospitals and healthcare systems — primarily Emergency Departments, phlebotomy teams, and infection control departments — where contamination of blood cultures drives unnecessary antibiotic use, extended inpatient stays (averaging two additional days per event), and avoidable costs estimated at $16,000-$111,000 per false-positive event. Named reference customers include Crouse Hospital, Bayfront Health, Temple VA Hospital, The Ohio State University Wexner Medical Center, Stillwater Medical Center, and Guy's and St. Thomas' NHS Foundation Trust, with documented contamination-rate reductions of 54%-90% across peer-reviewed studies.\n\nKurin generates revenue primarily through hardware sales of disposable blood culture collection sets, with secondary revenue from clinical education, implementation support, compliance monitoring, and customer success services that drive adoption and retention. The company runs an enterprise field-sales motion supported by clinical specialists and customer success teams, and reaches customers through GPO contracts with all major U.S. healthcare GPOs: Premier Inc. (3-year Med/Surg agreement effective December 2018 covering ~4,000 U.S. hospitals and 165,000 providers), Vizient (named 2023 Diverse Supplier of the Year), Intalere, and AllSpire Health GPO. CE Mark approval received in May 2019 enabled European Economic Area distribution, with Guy's and St. Thomas' NHS Foundation Trust as an early UK clinical study site. Per-hospital cost-savings cases are well-documented ($185K annually at Crouse Hospital; $430K at Bayfront Health), although pricing is not publicly disclosed and individual hospital contracts are negotiated through GPO agreements.\n\nKurin is led by a four-person founding team (Bob Rogers, Dave Lloyd, Matt Heindel, Gino Kang) that previously built and scaled the CUROS disinfecting cap product line at Ivera Medical, which was acquired by 3M in 2015. CEO Bob Rogers has 45+ years in the medical device industry, 50+ issued U.S. and foreign patents, and was awarded 2014 Healthcare Entrepreneur of the Year by the San Diego Business Journal. The company holds a global IP portfolio of more than 25 issued patents across the U.S., Europe, Japan, China, Hong Kong, Australia, and Israel, with more than 20 pending applications, and in March 2026 the Federal Circuit affirmed a judgment of non-infringement in the company's favor in patent litigation with competitor Magnolia Medical Technologies (maker of Steripath). Only $2.32 million in disclosed outside equity funding (2016, Baker & Eastlack Ventures) appears in the record, suggesting the business has been scaled primarily through operating cash flow.

Name

Kurin

Legal name

Kurin, Inc.

Website

https://kurin.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Kurin is a privately held medical device company that develops FDA-cleared passive blood culture diversion devices, including the Kurin Lock and Kurin Jet, sold through GPO contracts and direct sales to U.S. hospitals to reduce contamination-driven false positives.

Ownership category

akta.pro rank

Product category

Blood Culture Collection Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)

akta.pro secondary industry

Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow) (HLAAALAG)

Keywords

• Blood culture collection
• Medical device manufacturing
• Infection prevention devices
• Passive blood diversion
• Clinical specimen collection

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Blood Culture Collection Sets (Hardware Sales): Kurin generates revenue from the sale of its Kurin blood culture collection sets and related devices (Kurin Lock, Kurin Jet, Kurin Advance). These are disposable medical devices sold to hospitals and healthcare systems. The company has achieved record revenues consistently quarter over quarter, indicating a recurring revenue stream from reorder customers.
2. Clinical Implementation and Support Services: Kurin provides clinical education, implementation support, compliance monitoring, and customer success services to hospital partners to drive device adoption and contamination rate reduction, contributing to product adoption and retention.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels6 records

Core offering

Kurin designs, manufactures, and sells disposable blood culture collection sets that use passive initial-specimen diversion technology to automatically divert the first 0.15 mL of blood (the portion most likely to contain skin contaminants) during venipuncture, then convey the remaining blood into culture bottles. The portfolio includes Kurin Lock (the original FDA 510(k)-cleared device), Kurin Jet (next-generation device for fastest path to less than 1% contamination), Kurin Advance (push-button safety needle), and peripheral IV accessories; clinical support and the Kurin Outcomes & Kurin Intelligence data platform are bundled with device sales to hospital customers.

Product overview

Kurin offers a portfolio of medical devices focused on reducing blood culture contamination in healthcare settings. The core product line includes Kurin Lock (the original passive diversion device), Kurin Jet (the fastest path to less than 1% contamination rates), and Kurin Advance (push-button safety needle). The company provides Kurin Outcomes & Kurin Intelligence for data analytics and educational resources, Kurin PIV18 for peripheral IV blood culture collection, and the Kurin Academy for clinician education. The 510(k)-cleared Kurin Blood Culture Collection Sets include butterfly needles (21g and 23g), PIV connectors, and culture bottle holders compatible with major blood culture systems (BD Bactec, BioMerieux BacT/Alert, ThermoFisher VersaTREK). The products automatically and passively divert potential skin contaminants during blood culture collection without requiring additional user steps.

Differentiator

Problem solved

Functional benefit

Brands

• Kurin Lock: The original blood culture collection set with automatic diversion technology for reducing contamination.
• Kurin Jet
• Kurin Advance
• Kurin Outcomes & Kurin Intelligence

Products and services

• Kurin Lock® The original Kurin blood culture collection device that automatically diverts approximately 0.15 mL of initial blood containing potential skin contaminants during venipuncture, then conveys subsequent blood flow through a separate channel into the culture bottle. Designed for hospitals and clinical laboratories to reduce false positive blood culture results.
• Kurin Jet® Next-generation blood culture diversion device positioned as the fastest path to less than 1% blood culture contamination rates for hospitals and health systems.
• Kurin Advance™ Push-button Safety Needle Push-button safety needle reimagined for blood culture collection, providing integrated sharps protection for clinicians in hospital settings.

Quantifiable outcome

• Contamination rate reduction from 10.4% to 2.7% (74% relative reduction) in ED pilot study
• +6 more outcomes

Named customers7 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• Stillwater Medical CenterminorStrategic or Co-development Partner · 18 April 2026Stillwater Medical Center presented a study comparing the impact of two diversion devices at SHEA 2026 (April 2026), evaluating Kurin's effectiveness against a competitor device.
• The Ohio State University Wexner Medical CenterminorStrategic or Co-development Partner · 6 August 2024Kurin works with The Ohio State University Wexner Medical Center on patient safety and increased access to high quality healthcare (announced August 2024).
• AllSpire Health GPOminorChannel Partner/ Reseller/ Distributor · 18 January 2022Kurin announced an agreement with AllSpire Health GPO to impact contaminated blood cultures. AllSpire serves a consortium of health systems.
• Guy's and St. Thomas' NHS Foundation TrustminorStrategic or Co-development Partner · 5 October 2021Guy's and St. Thomas' NHS Foundation Trust, a prestigious London-based hospital, conducted a clinical study on Kurin Lock and presented findings at the Infection Prevention Society conference in Liverpool. The study showed 66% reduction in blood culture contaminations with financial savings for the hospital.
• IntalereminorChannel Partner/ Reseller/ Distributor · 30 June 2020Kurin announced an agreement with Intalere for Kurin Lock to impact contaminated blood cultures. Intalere is a GPO serving healthcare providers.
• VizientcoreChannel Partner/ Reseller/ Distributor · 21 April 2020Kurin announced an agreement with Vizient for Kurin Lock to help reduce contaminated blood cultures. Vizient is one of the largest healthcare performance improvement companies in the U.S. Kurin was subsequently named Vizient's 2023 Diverse Supplier of the Year.
• Premier Inc.coreChannel Partner/ Reseller/ Distributor · 2 October 2018Kurin was awarded a Med/Surg Group agreement in the Safety Phlebotomy Category with Premier, effective December 1, 2018 for three years. Premier is a leading healthcare improvement company uniting approximately 4,000 U.S. hospitals and 165,000 other providers. This agreement allows Premier members to access special pricing and terms pre-negotiated by Premier for Kurin blood culture products.
• Crouse HospitalcoreStrategic or Co-development Partner · 1 January 2017Crouse Hospital adopted Kurin Lock in their emergency department in January 2017, reducing contamination rates from 1.6% to 0.8% and achieving annual cost savings of over $185,000. The partnership expanded institution-wide and resulted in a peer-reviewed publication in the Journal of Critical Nurse Specialists in 2018. The hospital has been a reference customer for Kurin.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Magnolia Medical Technologies: Maker of Steripath, the primary directly competing initial specimen diversion device for blood culture collection. Compared head-to-head with Kurin at Temple VA Hospital; competes in the same hospitals for the same clinical workflow.

Broad incumbents

• Becton Dickinson (BD): Major medical device incumbent and maker of BD BACTEC blood culture bottle systems, which are directly compatible with Kurin's collection sets. Operates broadly across hospital diagnostics, injection, and vascular access.
• bioMérieux: Global diagnostics incumbent whose BacT/Alert blood culture detection systems are compatible with Kurin collection sets. Operates broadly in clinical microbiology and IVD.
• Thermo Fisher Scientific: Major life sciences and diagnostics incumbent whose VersaTREK REDOX blood culture systems are compatible with Kurin devices. Operates broadly across diagnostics and laboratory products.
• 3M: Diversified medical products incumbent and acquirer of Ivera Medical (the prior company founded by Kurin's current leadership) in 2015. Operates broadly in healthcare, safety, and infection prevention categories overlapping with Kurin's positioning.
• ICU Medical: Medical device incumbent specializing in IV therapy, safety needles, and vascular access products adjacent to Kurin Advance push-button safety needle and Kurin PIV18 peripheral IV configuration.
• Teleflex: Broad medical device incumbent with strong vascular access and safety needle portfolio, adjacent to Kurin's blood culture collection sets and safety needle offerings.
• B. Braun: Global medical device and IV therapy incumbent with safety needle and infusion product lines that overlap with Kurin Advance and Kurin PIV18 use cases in hospital phlebotomy.

Emerging players

• Velano Vascular: Emerging medical device company focused on needle-free blood draw technology (PIVO), which represents an alternative blood collection approach with potential long-term implications for conventional phlebotomy workflows including blood cultures.
• Tasso Inc. Emerging player developing at-home and point-of-care capillary blood collection devices for diagnostics, representing an alternative sampling paradigm that could influence the future of clinical blood collection workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kurin

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kurin